The guidelines for the treatment of atopic dermatitis (AD) issued by the Japanese Dermatological Association (JDA), which are basically designed for dermatologists, were first prepared in 2000 and revised in 2016. The guidelines for AD of the Japanese Society of Allergology (JSA), which are basically designed for allergologists, including internists, otorhinolaryngologists, ophthalmologists, and dermatologists, were first prepared in 2009 and revised in 2014. In this article, I review the definition, pathophysiology, etiology, epidemiology, diagnosis, severity classification, examination for diagnosis and severity assessment, and treatments for AD in Japan according to these two guidelines for AD (JDA and JSA).
Introduction
The guidelines for the treatment of atopic dermatitis In the chronic stage, Th1 cells producing interferon (IFN)-γ and IL-12 also play an important role in the pathogenesis of AD 10 . In addition, the number of Th17 cells is increased in the peripheral blood and acute lesional skin of AD
11
. Interestingly, the Asian AD phenotype including Japanese presents a blended phenotype between that of European American patients with AD and those with psoriasis, which is known to be a Th17 dominant skin disease, including increased hyperplasia, parakeratosis, higher Th17 activation, and a strong Th2 
B. Skin Dysfunction
In AD patients the skin barrier function is reduced and skin irritability to nonspecific stimuli is enhanced, fre- nerve density that leads to hypersensitivity to pruritus 16 .
Etiology
AD is caused by a combination of genetic and environmental factors 3 .
A. Genetic Factors
Association studies in populations of diverse ancestry, meta-analysis of studies and genome-wide association study (GWAS) have shown that mutation in FLG (encoding filaggrin) is strongly associated with AD 17 20 . In addi- 
B. Etiological and Exacerbating Factors
Numerous of etiological and exacerbating factors have been proposed, with the importance level of each varying among age groups and individual patients 3 . These factors include foods, sweat, physical irritation including scratching, environmental factors, microbes/fungi, contact allergens, and stress. It is commonly experienced that sweat induces itch, leading to the aggravation of AD.
Clinically, psychological stress is well known to exacerbate AD symptoms, especially from the second half of childhood to adulthood 3 . 2003 by the ISAAC, few nations showed a significant decrease in the prevalence in children 6 to 7 years old compared with the prevalence in the phase I study 23 . For children 13 to 14 years old, the AD prevalence decreased in some previously high-prevalence centers in the industrialized world such as the UK and New Zealand.
Epidemiology

A. Global Prevalence of AD
B. Epidemiological Survey in Japan
A nationwide prevalence survey was performed in Japan from 2000 to 2008 using the medical examination data from public health centers, elementary schools, and universities. Figure 2 
B. Diagnostic Criteria of Hanifin and Rajka
The diagnostic criteria defined by Hanifin and Rajka in 1980 are frequently used worldwide 28 . One of the differences between their criteria and the JDA criteria is that a personal or family history of atopic diseases is defined as a basic feature in the former, and as a diagnostic aid in the latter. However, atopic diathesis is clearly addressed in the definition of AD by the JDA ( Table 1) 1 .
Severity Classification
A. Severity Classification for the Whole Body
The classification of the severity of AD prepared by the Severity Classification-Reviewing Committee of the JDA is available for clinical studies because its statistical reliability and usefulness have been verified (Fig. 3 .
B. Severity of Eruption
The primary treatment, application of a topical corticosteroid, should be determined based on "the severity of each eruption" ( Table 2) 2 . Briefly, potent topical therapy is selected to treat severe eruption even when its extent is narrow. However, it is not required for patients with mild eruption even when its area is extensive.
Therefore, "the severity of each eruption" is the most important factor to consider when selecting topical therapy 2 .
Examination for Diagnosis and Severity Assessment
A. Serum IgE Level
Total serum IgE levels are high in about 80% of AD This severity classification can be adopted only for the cases that are definitely diagnosed as atopic dermatitis.
Three elements of eruption are evaluated in the most severely affected part of each of the five body regions (15 times in total).
The areas of eruption on the five body regions are also evaluated (5 times in total). Both scores are totalized (20 times in total).
For evaluation of severity of eruption on each region, the severest part is selected for each element.
Evaluation of the area of eruption should be done considering all three elements for all five body regions.
The highest possible score is 60 points. patients. This parameter is useful for diagnosis. The total serum IgE level reflects the long-term severity and activity of AD, but not its short-term changes. IgE antibodies may be produced in AD patients in response to several allergens such as mites, house dust, pollen, fungi, and foods 2 .
Head / Neck
B. Peripheral Blood Eosinophil Counts, Serum Lactate Dehydrogenase (LDH) Levels, and TARC Levels
The parameters of the short-term severity and activity of AD include the peripheral blood eosinophil count, se-rum LDH level, and TARC level 7 . The serum TARC level more sensitively reflects AD activity than the serum IgE level, LDH level, and peripheral blood eosinophil count.
It may also be possible to review patient education and treatments by using the serum TARC level as a parameter 2 .
Treatments
A. Goal of Treatment
The goal of treatment is to reach and maintain a state in which symptoms are absent or mild without daily activities being disturbed by AD and drug therapy not being required. Even when this level is not reached, the objective is to maintain a state in which the symptoms are mild without rapid exacerbations that afflict daily activities 2 .
B. Treatment Measures
Treatment measures for AD basically consist of drug therapy, skin care, and elimination of exacerbating factors. These measures are important, and should be adequately combined for individual patients 2 .
C. Drug Treatment
Drugs that potently reduce AD-related inflammation in the skin are topical corticosteroids and tacrolimus. It is most important to promptly and accurately reduce inflammation related to AD by using these topical antiinflammatory drugs. Topical corticosteroids are classified into five ranks: strongest, very strong, strong, medium, and weak. It is important to adequately select drugs at a rank that matches the severity of each eruption ( Table   2) 2 . Generally, in infants/children, topical corticosteroids one rank lower than that presented in Table 2 
D. Skin Care
The water content of the stratum corneum is reduced in AD patients, leading to dry skin and reduced skin barrier function 32 . The use of moisturizers for the dry skin reverses the reduction in the water content of the stratum corneum, promoting recovery of the skin barrier function, preventing the recurrence of dermatitis, and inhibiting pruritus 2 .
E. Elimination of Exacerbating Factors
Daily/social life-related exacerbating factors specific to individual patients exist in most cases. It is important to investigate and eliminate such factors. For example, contact allergies to topical drugs, cosmetics, perfumes, metals, and shampoos may exacerbate skin eruptions. It is necessary to establish whether eruptions subside by avoiding contact with suspected substances, make a definitive diagnosis based on patch tests, and avoid them 2 .
F. Ultraviolet (UV) Therapy
Ultraviolet (UV) therapy is considered for patients with severe AD who do not respond to treatments with topical anti-inflammatory drugs, antihistamines, and moisturizers. In Japan, irradiation systems for narrowband UVB therapy with a peak of 311 nm have been installed in an increasing number of hospitals and clinics.
This therapy may be applied further because of its safety and the lack of a need for post-treatment light shielding 2 .
G. Hospital Care/Education
Hospital care is indicated for some severe cases in 
H. Adherence
In medical care for AD, it is important for patients and their families to understand the significance of treatments, positively participate in the selection of therapeutic strategies, accomplish treatments, and improve the will to continue treatments, that is, adherence to treatments. Health care professionals should explain the necessity of drug therapy and skin care to patients and motivate them 2 .
I. Treatment Procedures
Treatment procedures for AD are shown in Figure 4 2 .
After making an accurate diagnosis and evaluating the disease severity, appropriate treatment methods should be presented to patients in accordance with the state of 37 .
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